Starpharma : The Third Installment

Over the past two weeks I copped quite a bit of email flack from devout Starpharma (ASX : SPL) shareholders in response to my last (two) posts. Here is a pithy example: Long Tail, you are just a downramper and a f—–g idiot. You claim to know about science but you can’t see good results…

The Dark Side of Digital Diapers

It’s funny. I kept getting requests for more “positive” commentary in my writing. I kept getting challenged to help “accentuate the positive aspects” about Australian bioscience/healtchare companies, especially since US readership is fairly significant. My general position has generally been that you make good companies stand out by picking out the chaff, but maybe that was too…

Starpharma’s big AZ deal…

Today’s announcement of a “significant” deal with AstraZeneca will be welcome news for Starpharma (ASX : SPL) shareholders and will no doubt move the needle on the perception of progress by the company. I am sure that there will be a lot of high-fives on HotCopper today. While I think it is great news to see continued evidence…

Starpharma : Love the rubbers, less keen on the drugs…

Over the years, a number of people have asked me what I think about StarPharma (ASX : SPL), and the answer has changed a lot over time. Overall it’s a company I haven’t really bothered spending much time looking at because after its failed Phase III for VivaGel, I sort of figured it was burnt toast. The general consensus…